Pharnext to Present at the H.C. Wainwright Annual Global Life Sciences Conference
Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA) , a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that company management will present a corporate overview at the H.C. Wainwright Annual Global Life Sciences Conference .
The presentation will take place as follows:
- Date: Tuesday, April 10th , 2018
- Time: 2:10 pm CEST
- Venue: Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco
Pharnext’s first-in-class PLEODRUG™, PXT3003, is currently in an international Phase 3 trial for the treatment of the rare disease Charcot-Marie-Tooth disease type 1A. The results of this trial are expected before the end of 2018.
If you are interested in meeting the Pharnext management team during this event or if you need more information about Pharnext's participation, please send an email to firstname.lastname@example.org
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. The results of this trial are expected in the second half of 2018. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext has developed a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property, including several product or composition of matter patents already granted. The Company was founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics and is supported by a world-class scientific team.
Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN
For more information, visit www.pharnext.com .
Xavier Paoli, +33 (0)1 41 09 22 30
Chief Commercial Officer
Investor Relations (Europe)
MC Services AG
Anne Hennecke, +49 211 529252 22
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Matthew Shinseki, +1 212 362 1200
Financial Communication (France)
Stéphane Ruiz, +33 (0)1 56 88 11 15
Media Relations (Europe)
Caroline Carmagnol / Aurore Gangloff
+33 (0)1 44 54 36 64
Media Relations (U.S.)
Marion Janic, +1 212 223 4017
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CA-GILEAD-SCIENCES,-INC.23.7.2019 22:02:07 CEST | Press release
Gilead Announces Latest Data in Ongoing HIV Cure Research Program
NY-MOODY’S-ANALYTICS23.7.2019 17:32:03 CEST | Press release
Moody’s Analytics Wins Best Reporting System Provider in Waters Rankings
CA-GILEAD-SCIENCES-INC.23.7.2019 17:02:11 CEST | Press release
Gilead Presents New Findings on Profile of Descovy® for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada®
CA-VELODYNE-LIDAR23.7.2019 17:02:11 CEST | Press release
Velodyne Lidar Acquires Mapper.ai for ADAS Launch
UBS23.7.2019 16:14:08 CEST | Press release
Wealthy Americans are increasingly willing to invest, new UBS survey finds
NY-XANDR23.7.2019 15:02:14 CEST | Press release
Community Welcomes Three New Premium Media Brands
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom